Chemomab Therapeutics Ltd. American Depositary Share

Go to Chemomab Therapeutics Ltd. American Depositary Share Website

$1.00

0.00 (0.00%)
Live
Previous Close

$1

Day Range

$0 - $0

Previous Day Range

$0.99 - $1.05

Market Cap

$21.3 million USD

Day Vol.

0

Previous Day Vol.

162746

Currency

USD

Primary Exchange

Nasdaq

Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL2...


Community
  • 0 posts discussing
0

Watchers

0

Visitors


Recent News

Chemomab's CM-101 demonstrated anti-fibrotic, anti-inflammatory, and anti-cholestatic activity in a Phase 2 trial for primary sclerosing cholangitis, a rare liver disease. The data supports further clinical development of CM-101 for this condition.

Related tickers: CMMB.

Read Full Article

Chemomab Therapeutics reported positive Phase 2 results for its lead drug candidate CM-101 in primary sclerosing cholangitis, demonstrating safety and anti-fibrotic, anti-inflammatory, and anti-cholestatic activity. The company plans to advance CM-101 to a Phase 3 trial and is in discussions with potential partners.

Related tickers: CMMB.

Read Full Article
Trending Tickers

Please sign in to view